Delivering Unprecedented Access to Biosimilars in Global Markets
  • Developing, Manufacturing and Commercializing
    Biosimilar Products for Global Markets
Who We Are

Epirus is a biopharmaceutical company focused on the global development and commercialization of biosimilar monoclonal antibodies. Epirus’s strategy addresses the fragmented and complex global regulatory and commercial landscape for biosimilars and leverages market insights with close local collaborations to gain competitive advantages in target markets.

Learn More

News & Events

February 5, 2015

EPIRUS Biopharmaceuticals to Present at Leerink Global Healthcare Conference

January 30, 2015

EPIRUS Prices $48 Million Public Offering of Common Stock

Bookmark and Share